Safety and Efficacy of Anti-PD-1/PD-L1 Inhibitors Compared With Docetaxel for NSCLC: A Systematic Review and Meta-Analysis

被引:10
作者
Ma, Long [1 ,2 ]
Jin, Gang [2 ]
Yao, Keying [3 ]
Yang, Yi [2 ]
Chang, Ruitong [2 ]
Wang, Wenhao [2 ]
Liu, Jiawei [2 ]
Zhu, Zijiang [2 ]
机构
[1] Gansu Univ Chinese Med, Gansu Prov Hosp, Clin Med Coll 1, Lanzhou, Peoples R China
[2] Gansu Prov Hosp, Dept Thorac Surg, Lanzhou, Peoples R China
[3] Lanzhou Univ, Clin Med Coll 2, Lanzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
anti-PD-1; PD-L1; inhibitors; DOCETAXEL; systematic review; meta-analysis; NSCLC; CELL LUNG-CANCER; OPEN-LABEL; ATEZOLIZUMAB; MULTICENTER; NIVOLUMAB; DIAGNOSTICS; PHASE-3;
D O I
10.3389/fphar.2021.699892
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To evaluate the efficacy and safety of anti-PD-1/PD-L1 Inhibitors versus docetaxel for non-small cell lung cancer by meta-analysis. Methods: Randomized controlled trials (RCTs) about anti-PD-1/PD-L1 Inhibitors versus docetaxel on the treatment of NSCLC were searched in CNKI, WF, VIP, PubMed, EMBASE, Cochrane Library, and Web of Science databases. Two reviewers independently screened literature, extracted data and evaluated the risk of bias of eligible studies. Meta-analysis was performed by RevMan5.3 software. Results: Compared with the use of docetaxel chemotherapy for NSCLC, the overall survival and progression-free survival of the anti-PD-1/PD-L1 Inhibitors regimen are better [overall survival: (HR= 0.73, 95%CI:0.69 similar to 0.77, P<0.00001], progression-free survival: (HR= 0.89, 95%CI:0.83 similar to 0.94, P<0.00001]), and lower incidence of treatment-related grade 3 or higher adverse events ([OR=0.20, 95% CI: 0.13 similar to 0.31, P<0.00001]). Conclusion: Compared with the docetaxel chemotherapy regimen, the anti-PD-1/PD-L1 Inhibitors has certain advantages in terms of efficacy and safety. The results still need to be confirmed by a multi-center, large sample, and high-quality research.
引用
收藏
页数:8
相关论文
共 35 条
[1]   Development and characterization of octreotide-modified curcumin plus docetaxel micelles for potential treatment of non-small-cell lung cancer [J].
An, Quan ;
Shi, Chen-Xiao ;
Guo, Hao ;
Xie, Shi-Min ;
Yang, Ying-Ying ;
Liu, Ying-Nan ;
Liu, Zi-Hao ;
Zhou, Chang-Zheng ;
Niu, Feng-Ju .
PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 2019, 24 (09) :1164-1174
[2]   Lung cancer: some progress, but still a lot more to do [J].
不详 .
LANCET, 2019, 394 (10212) :1880-1880
[3]   Lung Cancer 2020 Epidemiology, Etiology, and Prevention [J].
Bade, Brett C. ;
Dela Cruz, Charles S. .
CLINICS IN CHEST MEDICINE, 2020, 41 (01) :1-+
[4]   Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC [J].
Barlesi, Fabrice ;
Garon, Edward B. ;
Kim, Dong-Wan ;
Felip, Enriqueta ;
Han, Ji-Youn ;
Kim, Joo-Hang ;
Ahn, Myung-Ju ;
Fidler, Mary Jo ;
Gubens, Matthew A. ;
de Castro, Gilberto, Jr. ;
Surmont, Veerle ;
Li, Qiao ;
Deitz, Anne C. ;
Lubiniecki, Gregory M. ;
Herbst, Roy S. .
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (05) :793-801
[5]   Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study [J].
Barlesi, Fabrice ;
Vansteenkiste, Johan ;
Spigel, David ;
Ishii, Hidenobu ;
Garassino, Marina ;
de Marinis, Filippo ;
Ozguroglu, Mustafa ;
Szczesna, Aleksandra ;
Polychronis, Andreas ;
Uslu, Ruchan ;
Krzakowski, Maciej ;
Lee, Jong-Seok ;
Calabro, Luana ;
Frontera, Osvaldo Aren ;
Ellers-Lenz, Barbara ;
Bajars, Marcis ;
Ruisi, Mary ;
Park, Keunchil .
LANCET ONCOLOGY, 2018, 19 (11) :1468-1479
[6]   Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer [J].
Bordoni, Rodolfo ;
Ciardiello, Fortunato ;
von Pawel, Joachim ;
Cortinovis, Diego ;
Karagiannis, Thomas ;
Ballinger, Marcus ;
Sandier, Alan ;
Yu, Wei ;
He, Pei ;
Matheny, Christina ;
Felizzi, Federico ;
Rittmeyer, Achim .
CLINICAL LUNG CANCER, 2018, 19 (05) :441-+
[7]   Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].
Borghaei, H. ;
Paz-Ares, L. ;
Horn, L. ;
Spigel, D. R. ;
Steins, M. ;
Ready, N. E. ;
Chow, L. Q. ;
Vokes, E. E. ;
Felip, E. ;
Holgado, E. ;
Barlesi, F. ;
Kohlhaeufl, M. ;
Arrieta, O. ;
Burgio, M. A. ;
Fayette, J. ;
Lena, H. ;
Poddubskaya, E. ;
Gerber, D. E. ;
Gettinger, S. N. ;
Rudin, C. M. ;
Rizvi, N. ;
Crino, L. ;
Blumenschein, G. R. ;
Antonia, S. J. ;
Dorange, C. ;
Harbison, C. T. ;
Finckenstein, F. Graf ;
Brahmer, J. R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639
[8]   Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].
Brahmer, Julie ;
Reckamp, Karen L. ;
Baas, Paul ;
Crino, Lucio ;
Eberhardt, Wilfried E. E. ;
Poddubskaya, Elena ;
Antonia, Scott ;
Pluzanski, Adam ;
Vokes, Everett E. ;
Holgado, Esther ;
Waterhouse, David ;
Ready, Neal ;
Gainor, Justin ;
Aren Frontera, Osvaldo ;
Havel, Libor ;
Steins, Martin ;
Garassino, Marina C. ;
Aerts, Joachim G. ;
Domine, Manuel ;
Paz-Ares, Luis ;
Reck, Martin ;
Baudelet, Christine ;
Harbison, Christopher T. ;
Lestini, Brian ;
Spigel, David R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135
[9]   Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC) [J].
Chae, Young Kwang ;
Arya, Ayush ;
Iams, Wade ;
Cruz, Marcelo R. ;
Chandra, Sunandana ;
Choi, Jaehyuk ;
Giles, Francis .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
[10]   Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer [J].
Fehrenbacher, Louis ;
von Pawel, Joachim ;
Park, Keunchil ;
Rittmeyer, Achim ;
Gandara, David R. ;
Aix, Santiago Ponce ;
Han, Ji-Youn ;
Gadgeel, Shirish M. ;
Hida, Toyoaki ;
Cortinovis, Diego L. ;
Cobo, Manuel ;
Kowalski, Dariusz M. ;
De Marinis, Filippo ;
Gandhi, Mayank ;
Danner, Bradford ;
Matheny, Christina ;
Kowanetz, Marcin ;
He, Pei ;
Felizzi, Federico ;
Patel, Hina ;
Sandler, Alan ;
Ballinger, Marcus ;
Barlesi, Fabrice .
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) :1156-1170